Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Million TOKYO, Jun 30, 2011 (BUSINESS WIRE) -- ...
The agency is adding data points to its Paragraph IV Patent Certifications List, which provides brand exclusivity information, in order to help generic-drug applicants determine if their product can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback